Key facts
- Invus Global Management, LLC filed SCHEDULE 13G for Bicycle Therapeutics plc Ordinary Shares, nominal value GBP 0.01 per share (BCYC).
- Disclosed ownership: 6.3%.
- Date of event: 25 Feb 2026.
Invus Global Management, LLC - 25 Feb 2026 SCHEDULE 13G Report for Bicycle Therapeutics plc Ordinary Shares, nominal value GBP 0.01 per share (BCYC)
- Filing Manager
- Invus Global Management, LLC
- Reporting Manager
- Raymond Debbane
- Symbol
- BCYC
- Shares outstanding
- 49,984,905 shares
- Disclosed Ownership
- 3,149,049 shares
- Ownership
- 6.3%
- Form type
- SCHEDULE 13G
- Filing time
- 03 Mar 2026, 17:39:55 UTC
- Date of event
- 25 Feb 2026
- Next filing
- 04 May 2026
- SEC
- View on sec.gov
Key filing fact
Invus Global Management, LLC disclosed 6.3% ownership in Bicycle Therapeutics plc Ordinary Shares, nominal value GBP 0.01 per share (BCYC) on 25 Feb 2026.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 03 Mar 2026, 17:39.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (8)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 5.4% | 2,719,707 | 2,719,707 | 0 | /s/ Raymond Debbane | Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner | |
| Invus Public Equities Advisors, LLC | 5.4% | 2,719,707 | 2,719,707 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Invus Global Management, LLC | 5.4% | 2,719,707 | 2,719,707 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Siren, L.L.C. | 5.4% | 2,719,707 | 2,719,707 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Avicenna Life Sci Master Fund LP | 0.9% | 429,342 | 429,342 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner | |
| Avicenna Life Sci Master GP LLC | 0.9% | 429,342 | 429,342 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer | |
| Ulys, L.L.C. | 0.9% | 429,342 | 429,342 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Raymond Debbane | 6.3% | 3,149,049 | 3,149,049 | 0 | /s/ Raymond Debbane | Raymond Debbane |
CIK / CUSIP context first